Pfizer (PFE) Receivables - Net (2009 - 2026)

Pfizer (PFE) has 18 years of Receivables - Net data on file, last reported at $12.6 billion in Q1 2026.

• Quarterly Receivables - Net rose 6.25% year-over-year to $12.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.6 billion (up 6.25% YoY) and the FY2025 annual result came in at $11.9 billion, up 3.59% from the prior year.
• Receivables - Net rose to $12.6 billion in Q1 2026 per PFE's latest filing, from $11.9 billion in the prior quarter.
• Across five years, Receivables - Net topped out at $16.1 billion in Q4 2022 and bottomed at $10.2 billion in Q3 2023.
• The 5-year median for Receivables - Net is $11.9 billion (2025), against an average of $12.4 billion.
• The widest annual swing landed in 2022, when Receivables - Net surged 43.15%; it then tumbled 32.49% in 2023.
• Tracing PFE's Receivables - Net over 5 years: stood at $11.0 billion in 2022, then advanced by 5.61% to $11.6 billion in 2023, then dropped by 0.89% to $11.5 billion in 2024, then increased by 3.59% to $11.9 billion in 2025, then advanced by 5.99% to $12.6 billion in 2026.
• Per Business Quant, the three latest PFE Receivables - Net figures stand at $12.6 billion (Q1 2026), $11.9 billion (Q4 2025), and $14.3 billion (Q3 2025).

Peer Comparison